↓ Skip to main content

Safety Reporting and Adverse-Event Profile of Mirtazapine Described in Randomized Controlled Trials in Comparison with Other Classes of Antidepressants in the Acute-Phase Treatment of Adults with…

Overview of attention for article published in CNS Drugs, August 2012
Altmetric Badge

About this Attention Score

  • Average Attention Score compared to outputs of the same age

Mentioned by

wikipedia
4 Wikipedia pages

Citations

dimensions_citation
78 Dimensions

Readers on

mendeley
146 Mendeley
Title
Safety Reporting and Adverse-Event Profile of Mirtazapine Described in Randomized Controlled Trials in Comparison with Other Classes of Antidepressants in the Acute-Phase Treatment of Adults with Depression
Published in
CNS Drugs, August 2012
DOI 10.2165/11319480-000000000-00000
Pubmed ID
Authors

Norio Watanabe, Ichiro M. Omori, Atsuo Nakagawa, Andrea Cipriani, Corrado Barbui, Hugh McGuire, Rachel Churchill, Toshi A. Furukawa

Abstract

Mirtazapine has a unique mechanism of antidepressant action, and thus is thought to have a different profile of adverse events from that of other antidepressants.

Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 146 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Brazil 2 1%
Switzerland 2 1%
New Zealand 1 <1%
India 1 <1%
Unknown 140 96%

Demographic breakdown

Readers by professional status Count As %
Researcher 27 18%
Student > Master 21 14%
Student > Ph. D. Student 15 10%
Student > Bachelor 14 10%
Student > Doctoral Student 12 8%
Other 30 21%
Unknown 27 18%
Readers by discipline Count As %
Medicine and Dentistry 59 40%
Psychology 18 12%
Nursing and Health Professions 8 5%
Agricultural and Biological Sciences 8 5%
Neuroscience 4 3%
Other 16 11%
Unknown 33 23%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 3. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 26 September 2020.
All research outputs
#8,534,976
of 25,374,647 outputs
Outputs from CNS Drugs
#768
of 1,388 outputs
Outputs of similar age
#64,269
of 187,955 outputs
Outputs of similar age from CNS Drugs
#275
of 541 outputs
Altmetric has tracked 25,374,647 research outputs across all sources so far. This one is in the 43rd percentile – i.e., 43% of other outputs scored the same or lower than it.
So far Altmetric has tracked 1,388 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 11.6. This one is in the 23rd percentile – i.e., 23% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 187,955 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 44th percentile – i.e., 44% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 541 others from the same source and published within six weeks on either side of this one. This one is in the 10th percentile – i.e., 10% of its contemporaries scored the same or lower than it.